KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Gross Profit (2019 - 2025)

Esperion Therapeutics' Gross Profit history spans 7 years, with the latest figure at $46.0 million for Q3 2025.

  • For Q3 2025, Gross Profit rose 33.99% year-over-year to $46.0 million; the TTM value through Sep 2025 reached $176.8 million, down 26.65%, while the annual FY2024 figure was $263.7 million, 260.92% up from the prior year.
  • Gross Profit reached $46.0 million in Q3 2025 per ESPR's latest filing, down from $53.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $127.7 million in Q1 2024 to a low of $6.2 million in Q1 2021.
  • Average Gross Profit over 5 years is $30.7 million, with a median of $20.6 million recorded in 2023.
  • Peak YoY movement for Gross Profit: tumbled 81.66% in 2021, then skyrocketed 907.02% in 2024.
  • A 5-year view of Gross Profit shows it stood at $10.3 million in 2021, then soared by 41.95% to $14.7 million in 2022, then surged by 41.89% to $20.8 million in 2023, then skyrocketed by 109.07% to $43.5 million in 2024, then grew by 5.84% to $46.0 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Gross Profit are $46.0 million (Q3 2025), $53.8 million (Q2 2025), and $33.5 million (Q1 2025).